Revenue
2022
2023
2024
2025
Contineum Therapeutics, Inc. (CTNM)
Price$17.03Cached quote
Net income
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $50.0M | $0 |
| Research & development | $51.5M | $38.4M | $27.6M | $16.9M |
| Operating expenses | $68.1M | $50.9M | $33.9M | $22.7M |
| Operating income | −$68.1M | −$50.9M | $16.1M | −$22.7M |
| Operating margin | — | — | 32.15% | — |
| EBITDA | −$67.7M | −$50.6M | $16.3M | −$23.5M |
| EBITDA margin | — | — | 32.54% | — |
| Net income | −$60.0M | −$42.3M | $22.7M | −$24.3M |
| Net profit margin | — | — | 45.44% | — |
| Basic EPSper basic share | -$2.17 | -$2.18 | $1.36 | -$1.45 |
| Diluted EPSper diluted share | -$2.17 | -$2.18 | $0.08 | -$1.45 |
Owners
Reported shareholders
8.62%of listed shares
MONTANOVA CAPITAL, LLC2.84M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
MONTANOVA CAPITAL, LLC | 8.62%2.84M shares |
Jupiter Topco LLC | 8.30%2.73M shares |
BlackRock, Inc. | 6.26%2.06M shares |
JOHNSON & JOHNSON | 6.01%1.98M shares |
FRANKLIN RESOURCES INC | 5.58%1.84M shares |
Balyasny Asset Management L.P. | 4.62%1.52M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 4.01%1.32M shares |
PERCEPTIVE ADVISORS LLC | 3.81%1.26M shares |
FMR LLC | 3.16%1.04M shares |
MILLENNIUM MANAGEMENT LLC | 2.83%931.71K shares |
GREAT POINT PARTNERS LLC | 2.80%921.48K shares |
Longaeva Partners L.P. | 2.47%812.76K shares |
Ikarian Capital, LLC | 2.45%807.87K shares |
SECTORAL ASSET MANAGEMENT INC | 2.21%727.59K shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.10%693.19K shares |
HHLR ADVISORS, LTD. | 2.03%669.34K shares |
RED TREE MANAGEMENT, LLC | 1.94%638.16K shares |
Versant Venture Management, LLC | 1.65%542.63K shares |
GOLDMAN SACHS GROUP INC | 1.51%497.26K shares |
Boxer Capital Management, LLC | 1.50%494K shares |
Percentages use 32.95M shares of this listed class outstanding on Jun 30, 2026.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 1, 2026Form 4 · 10b5-1 | Lorrain Daniel S.Chief Scientific Officer | SellClass A Common Stock | 4.2K | $13.16 | $54.9K | 139.4K |
| May 1, 2026Form 4 · 10b5-1 | Lorrain Daniel S.Chief Scientific Officer | SellClass A Common Stock | 300 | $13.84 | $4.2K | 143.5K |
| May 1, 2026Form 4 · 10b5-1 | Lorrain Daniel S.Chief Scientific Officer | SellClass A Common Stock | 3.9K | $13.06 | $50.5K | 143.8K |
| Apr 6, 2026Form 4 · 10b5-1 | Lorrain Daniel S.Chief Scientific Officer | SellClass A Common Stock | 4.2K | $13.43 | $56.0K | 147.7K |
| Mar 2, 2026Form 4 · 10b5-1 | Lorrain Daniel S.Chief Scientific Officer | SellClass A Common Stock | 4.2K | $15.01 | $62.6K | 151.9K |